Results 81 to 90 of about 2,895 (208)

Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders

International Journal of Nephrology, 2018
Background. Hyperphosphatemia in chronic kidney disease (CKD) patients is often treated with calcium carbonate (CaCO3) despite the fact that CaCO3 is associated with increased calcium load and potentially increased cardiovascular risk.
B. L. Goh, A. Soraya, A. Goh, K. L. Ang
doaj   +1 more source

Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study

BMC Nephrology, 2017
Background Vascular calcification is a major contributing factor to mortality in end stage renal disease (ESRD). Despite the efficacy of phosphate binders to improve hyperphosphatemia, data on vascular calcification are less clear.
A. Neradova, S. P. Schumacher, I. Hubeek, P. Lux, L. J. Schurgers, M. G. Vervloet   +5 more
doaj   +1 more source

Safety and Phosphate‐Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers

Clinical and Translational Science, Volume 18, Issue 1, January 2025.
ABSTRACT Despite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end‐stage kidney disease on dialysis. Characteristics of currently available phosphate binders that lead to poor patient experiences such as large drug volume size of required daily medication (e.g., many ...
Pablo E. Pergola, Melanie S. Joy, Armando Garsd, Steve J. Hasal, Atul Khare, Guru Reddy, Pramod Gupta, William F. Finn   +7 more
wiley   +1 more source

Hypophosphatemic effect of niacin extended release in ischemic kidney disease [PDF]

, 2015
Ischemic nephropathy is an emerging cause of end stage renal disease, associated with many co-morbidities especially cardiovascular disease risk and derangement in calcium-phosphorus homeostasis resulting in hyperphosphatemia, influencing bones, a ...
Dawani, Manohar Lal, Mahboob, Tabassum, Yasmeen, Ghazala   +2 more
core   +1 more source

Calciphylaxis in the Upper GI Tract in an ESRD Patient: An Atypical Presentation and Review of Literature

Case Reports in Nephrology, Volume 2025, Issue 1, 2025.
Calciphylaxis, also referred to as calcific uremic arteriolopathy (CUA), is a rare and life‐threatening condition characterized by vascular calcification, ischemic tissue injury, and high morbidity and mortality. It is predominantly observed in patients with end‐stage renal disease (ESRD) who are undergoing dialysis and typically presents with painful ...
Pallavi D. Shirsat, Kunal Sonavane, Leonardo Ramirez Botana, Bharat Sachdeva, Poorani Gurumallesh   +4 more
wiley   +1 more source

Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. [PDF]

, 2013
p-Cresol is a by-product of the metabolism of aromatic aminoacid operated by resident intestinal bacteria. In patients with chronic kidney disease, the accumulation of p-cresol and of its metabolite p-cresyl-sulphate, that represents more than 95% of ...
ARGENTINO, GENNARO, BARBATO, FRANCESCO, Borrelli S, CATALDI, MAURO, GRUMETTO, LUCIA, GUIDA, BRUNA, Memoli A, MEMOLI, BRUNO, POTA, ANDREA, RICCIO, ELEONORA, SALERNO, GIULIANA   +10 more
core   +2 more sources

Evaluation of Compliance With International Guidelines During the Follow‐Up of Hypoparathyroidism

International Journal of Endocrinology, Volume 2025, Issue 1, 2025.
Aims: Hypoparathyroidism is a disorder that causes renal complications, bone disease, an increased risk of cardiovascular diseases, neuromuscular complications, and ocular findings. In this study, we aimed to determine how well the existing guidelines were followed in the follow‐up of patients with hypoparathyroidism.
Beril Turan Erdogan, Sefika Burcak Polat, Caglar Keskin, Narin Nasiroglu İmga, Didem Ozdemir, Oya Topaloglu, Reyhan Ersoy, Bekir Cakir, Suraiya Saleem   +8 more
wiley   +1 more source

The effect of intravenous vitamin C on the phosphorus level reduction in hemodialysis patients: A double blind randomized clinical trial [PDF]

, 2012
Aim The majority of hemodialysis patients are hyperphosphate-mic. Hyperphosphatemia in these patients can lead to renal oste-odystrophy, vascular calcifcation, cardiovascular events, and is independently associated with mortality risk.
Aarabi, M., Baradari, A.G., Espahbodi, F., Zeydi, A.E.   +3 more
core  

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis [PDF]

, 2015
AIMS: In Spain, the first line treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) consists of calciumbased phosphate binders (CB). However, their use is associated with vascular calcification and an increased mortality risk.
Antonio Galán, Blanca Gros, Emilio González-Parra, Itziar Oyagüez, Jose A Herrero, Keith Tolley, Maria Echave, Stefan Vegter   +7 more
core   +1 more source

Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.

PLoS ONE, 2016
BackgroundChronic kidney disease-mineral and bone disorder (CKD-MBD) has been linked to poor health outcomes, including diminished quality and length of life. This condition is characterized by high phosphate levels and requires phosphate-lowering agents-
Nigar Sekercioglu, Lehana Thabane, Juan Pablo Díaz Martínez, Gihad Nesrallah, Christopher J Longo, Jason W Busse, Noori Akhtar-Danesh, Arnav Agarwal, Reem Al-Khalifah, Alfonso Iorio, Gordon H Guyatt   +10 more
doaj   +1 more source